A New Method for Determining Concentrations of Direct Oral Anticoagulants

Bloemen, Saartje; Zwaveling, Suzanne; Douxfils, Jonathan; Peters, T.; Wagenvoord, Rob; Hemker, Hendrick Coenraad; Mullier, François; de Laat, Bas; Roest, Mark; Kremers, Romy

Published in:
Research and practice in thrombosis and haemostasis

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Link to publication
Citation for published version (HARVARD):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
A New Method for Determining Concentrations of Direct Oral Anticoagulants

S. Bloemen1,2, S. Zwaveling1,2, J. Douxfils3, T. Peters1,2, R. Wagenvoord1,2, H.C. Hemker1,2, F. Mullier3,4, B. de Laat1,2, M. Roest1,2, R. Kremers1,2

1Synapse Research Institute, CARIM, Maastricht University, Maastricht, The Netherlands, 2CARIM, Maastricht University, Department of Biochemistry, Maastricht, The Netherlands, 3Namur Research Institute for Life Sciences, University of Namur, Department of Pharmacy, Namur, Belgium, 4Université Catholique de Louvain, CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center, Yvoir, Belgium

Background: Direct oral anticoagulants (DOACs) are commonly provided without monitoring. However, reliable assays to measure DOAC levels and activity in emergency situations are needed. We developed a test based on the inhibition of $\alpha_2$-macroglobulin-thrombin ($\alpha_2$M-IIa) by dabigatran (DAB) and of $\alpha_2$M-factor Xa ($\alpha_2$M-Xa) by rivaroxaban (RIV), making it possible to evaluate both DOAC classes in combination with thrombin generation (TG).

Aims: To quantify DOAC levels and activity in plasma.

Methods: Consenting patients using RIV (n=50) and DAB (n=28) were included. TG was performed in platelet poor plasma (5 pM tissue factor), with idarucizumab in calibrator wells for DAB samples. The new DOAC assays measured the effect of diluted plasma samples on Z-Gly-Gly-Arg-AMC conversion by $\alpha_2$M-Xa or $\alpha_2$M-IIa.

Results: A concentration of 30 nM $\alpha_2$M-Xa or $\alpha_2$M-IIa was optimal to measure 50-500 nM RIV/DAB and 90 nM $\alpha_2$M-Xa or 70 nM $\alpha_2$M-IIa, respectively were optimal for 500-1000 nM RIV/DAB (Fig.1).

The intra- and inter-assay CV were below 2.5 % and 5% (n=2). Both the RIV and DAB assay correlated with TG parameters. The RIV assay correlated with ‘classical’ assays and had a very good correlation with Biophen DiXaI. The DAB assay did not correlate with hemoclot thrombin inhibitor (probably since DAB concentrations were too low), but showed variable correlation with the other assays (Table1).

Conclusions: The new DOAC assays show good correlations with other assays that were confirmed to accurately assess DOAC levels (particularly the RIV assay with the Biophen DiXal, which had the best correlation with mass spectrometry). Our assay can simultaneously evaluate DOAC concentrations as well as the DOACs effect on thrombin generation, providing an overview of the anticoagulation status of a patient in relation to circulating DOAC levels.

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** Dose-response of several DOAC concentrations at chosen $\alpha$2M-Xa and $\alpha$2M-IIa concentrations

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Correlation (Spearman) of rivaroxaban or dabigatran concentration (as determined by the new assay) with TG and other calibrated assays</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assay</strong></td>
<td><strong>Correlation coefficient</strong></td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>0.468</td>
</tr>
<tr>
<td>Calibrated prothrombin time (ng/ml)</td>
<td></td>
</tr>
<tr>
<td>Dilute Russel viper venom time (s)</td>
<td>0.760</td>
</tr>
<tr>
<td>Biophen DiXal (ng/ml)</td>
<td>0.915</td>
</tr>
<tr>
<td>TG endogenous thrombin potential(nM.min)</td>
<td>-0.525</td>
</tr>
<tr>
<td>TG Peak (nM)</td>
<td>-0.550</td>
</tr>
<tr>
<td>TG lag time (min)</td>
<td>0.671</td>
</tr>
<tr>
<td>TG time-to-peak (min)</td>
<td>0.702</td>
</tr>
<tr>
<td>TG time-to-peak (min)</td>
<td>0.339</td>
</tr>
</tbody>
</table>